JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shukla, V. K.
Right arrow Articles by Lemaire, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shukla, V. K.
Right arrow Articles by Lemaire, S.

Vol. 283, Issue 2, 604-610, 1997

Nonopioid Motor Effects of Dynorphin A and Related Peptides: Structure Dependence and Role of the N-Methyl-D-aspartate Receptor1

Vijay K. Shukla, Jyoti A. Prasad and Simon Lemaire

Department of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Dynorphin (Dyn) A and related opioid and nonopioid peptides were tested for their ability to produce motor effects in mice. Central (intracerebroventricular) administration of Dyn A in mice produced marked motor effects characterized by wild running, jumping, circling and/or barrel rolling with an ED50 value of 14.32 (95% confidence limits, 10.09-20.32) nmol/mouse. The order of potency of the various Dyn A-related peptides and fragments in producing motor effects was Dyn A sime  Dyn A-(1-13) > [Ala1]Dyn A-(1-13) sime  Dyn A-(2-13) > alpha -Neo-End > Dyn A-(1-8) sime  Dyn B sime  Dyn A-(2-8) >>> Dyn A-(3-8). Dyn A-(1- 5) (or Leu-Enk) and Dyn A-(6-10) displayed no motor effect at doses up to 100 nmol/mouse. The potencies of Dyn A and Dyn A-(2-13) were not affected by preadministration of naloxone (5 mg/kg s.c.), but the motor effects of Dyn A-(1-13) (20 nmol/mouse i.c.v.) were significantly reduced by coadministration of low doses (0.2-0.6 nmol/mouse) of the N-methyl-D-aspartate (NMDA) receptor antagonists dextrorphan, MK-801 and CPP. Dyn A was also a potent inhibitor of the binding of the phencyclidine receptor ligand, [3H]MK-801, to rat brain membranes, with a Ki value of 0.41 µM. However, the order of potency of the various Dyn A-related peptides and fragments in inhibiting [3H]MK-801 binding did not correlate with their ability to produce motor effects. On the other hand, Dyn A and related peptides produced a significant potentiation of the binding of the competitive NMDA antagonist [3H]CGP-39653 to rat brain membranes, an effect that correlated well (r = 0.91) with their potency in producing motor effects. These results indicate that the nonopioid motor effects of Dyn A and related peptides are structure dependent, with Dyn A-(2-8) being the minimal core peptide for motor activity. In addition, these effects most likely involve the participation of the excitatory amino acid binding domain on the NMDA receptor complex.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
BrainHome page
S. Loacker, M. Sayyah, W. Wittmann, H. Herzog, and C. Schwarzer
Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors
Brain, April 1, 2007; 130(4): 1017 - 1028.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
L. Koetzner, X.-Y. Hua, J. Lai, F. Porreca, and T. Yaksh
Nonopioid Actions of Intrathecal Dynorphin Evoke Spinal Excitatory Amino Acid and Prostaglandin E2 Release Mediated by Cyclooxygenase-1 and -2
J. Neurosci., February 11, 2004; 24(6): 1451 - 1458.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. Zimmer, E. Valjent, M. Konig, A. M. Zimmer, P. Robledo, H. Hahn, O. Valverde, and R. Maldonado
Absence of Delta -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice
J. Neurosci., December 1, 2001; 21(23): 9499 - 9505.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. M. Laughlin, A. A. Larson, and G. L. Wilcox
Mechanisms of Induction of Persistent Nociception by Dynorphin
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 6 - 11.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, T. J. Harris, A. Perez, and M.-J. Kreek
Effects of Systemically Administered Dynorphin A(1-17) in Rhesus Monkeys
J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 678 - 686.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.